Journal
DRUG DISCOVERY TODAY
Volume 21, Issue 3, Pages 454-464Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2016.01.016
Keywords
-
Categories
Funding
- NIMH NIH HHS [R01 MH105910, R01 MH093897] Funding Source: Medline
Ask authors/readers for more resources
Major depression is a chronic and debilitating illness that effects approximately 1 in 5 people, but currently available treatments are limited by low rates of efficacy, therapeutic time lag, and undesirable side effects. Recent efforts have been directed towards investigating rapid-acting agents that reverse the behavioral and neuronal deficits of chronic stress and depression, notably the glutamate NMDA receptor antagonist ketamine. The cellular mechanisms underlying the rapid antidepressant actions of ketamine and related agents are discussed, as well as novel, selective glutamatergic receptor targets that are safer and have fewer side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available